Clinical Trial Update: A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

Long-term Phase 2/3 study of MP-214 in schizophrenia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MP-214

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-04-13